Tourmaline Bio, Inc. (TRML)

NASDAQ: TRML · Real-Time Price · USD
21.65
+2.31 (11.92%)
Sep 18, 2024, 3:14 PM EDT - Market open
11.92%
Market Cap 555.01M
Revenue (ttm) n/a
Net Income (ttm) -49.29M
Shares Out 25.64M
EPS (ttm) -2.95
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 230,168
Open 19.37
Previous Close 19.34
Day's Range 19.37 - 22.06
52-Week Range 9.18 - 48.31
Beta n/a
Analysts Strong Buy
Price Target 61.80 (+185.52%)
Earnings Date Nov 12, 2024

About TRML

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company’s development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known a... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2021
Employees 44
Stock Exchange NASDAQ
Ticker Symbol TRML
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for TRML stock is "Strong Buy." The 12-month stock price forecast is $61.8, which is an increase of 185.52% from the latest price.

Price Target
$61.8
(185.52% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Tourmaline Bio to Present at Upcoming Investor Conferences

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve t...

15 days ago - GlobeNewsWire

Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights

– First patient dosed in May 2024 in Phase 2 TRANQUILITY trial evaluating pacibekitug (TOUR006) in patients with high cardiovascular risk – – On track to initiate a pivotal Phase 3 trial evaluating pa...

5 weeks ago - GlobeNewsWire

Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024

Phase 2 TRANQUILITY trial is evaluating the high-sensitivity C-reactive protein (hs-CRP)-lowering effect, safety, tolerability, and pharmacokinetics (PK) of quarterly and monthly subcutaneous administ...

6 weeks ago - GlobeNewsWire

Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer

NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve th...

2 months ago - GlobeNewsWire

Tourmaline Bio to Present at the Jefferies Global Healthcare Conference

NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the...

4 months ago - GlobeNewsWire

Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial

– First patient dosed in trial to evaluate the safety, pharmacokinetics and pharmacodynamics of TOUR006 in patients with inflammatory risk and chronic kidney disease – – Topline data anticipated in th...

4 months ago - GlobeNewsWire

Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights

– Initiated Phase 2 TRANQUILITY trial in April 2024 following U.S. FDA clearance of Investigational New Drug application (IND) for clinical development program in Atherosclerotic Cardiovascular Diseas...

4 months ago - GlobeNewsWire

Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

– Initiated pivotal spiriTED Phase 2b trial in Thyroid Eye Disease (TED) in 2023 and expanded TED clinical development plan, including accelerating the planned initiation of a pivotal Phase 3 trial in...

6 months ago - GlobeNewsWire

Tourmaline Bio to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve th...

8 months ago - GlobeNewsWire

Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

NEW YORK, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve ...

8 months ago - GlobeNewsWire

Tourmaline Bio Announces Pricing of Public Offering of Common Stock

NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve ...

8 months ago - GlobeNewsWire

Tourmaline Bio Announces Proposed Public Offering of Common Stock

NEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve ...

8 months ago - GlobeNewsWire

Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)

Tourmaline plans to accelerate the initiation of a pivotal Phase 3 trial in 2024 evaluating subcutaneous TOUR006 every 8 weeks as first-line treatment for TED, with topline data expected in 2026

9 months ago - GlobeNewsWire

Tourmaline Bio added to the NASDAQ Biotechnology Index

NEW YORK, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve ...

9 months ago - GlobeNewsWire

Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board

NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve ...

9 months ago - GlobeNewsWire

Tourmaline Bio: TED And ASCVD Targeting With Differentiated IL-6

Tourmaline Bio is advancing the use of its drug candidate TOUR006 for the treatment of thyroid eye disease and atherosclerotic cardiovascular disease. The ongoing phase 2b spiriTED study, which is usi...

11 months ago - Seeking Alpha

Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million

Tourmaline will be focused on advancing TOUR006, its differentiated anti-IL-6 antibody, to treat thyroid eye disease (TED), atherosclerotic cardiovascular disease (ASCVD) and other diseases

11 months ago - GlobeNewsWire

Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio

Combined Company to Trade on Nasdaq Under Ticker “TRML” Talaris Announces 1-for-10 Reverse Stock Split of Common Stock

1 year ago - GlobeNewsWire

Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio

Special dividend estimated to be $1.5118 per share Payment of special dividend conditioned upon closing of merger, which is subject to stockholder approval BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Ta...

1 year ago - GlobeNewsWire

New York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris Therapeutics

This acquisition expands Comprehensive Cell Solutions, a business unit of NYBCe, capabilities and geographic reach as a commercial-scale cell therapy clinical development and manufacturing organizatio...

1 year ago - GlobeNewsWire

TALARIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Talaris Therapeutics, Inc. - TALS

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Talaris Therap...

1 year ago - Business Wire

Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement

Merger to create Nasdaq-listed, late-stage clinical biotechnology company focused on developing Tourmaline's anti-IL-6 antibody (TOUR006) in thyroid eye disease (TED) and atherosclerotic cardiovascula...

1 year ago - GlobeNewsWire

Talaris Therapeutics Announces Leadership Transition

BOSTON and LOUISVILLE, Ky., May 26, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), today announced the appointment of Mary Kay Fenton as interim Chief Executive Officer and Presid...

1 year ago - GlobeNewsWire

Talaris Therapeutics Announces Plans to Explore Strategic Alternatives and Implements Restructuring Plan

BOSTON and LOUISVILLE, Ky., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), today announced that it has completed a review of its business and program prospects. Based on ...

1 year ago - GlobeNewsWire

Talaris Therapeutics to Participate at the 5th Annual Evercore ISI HealthCONx Conference

BOSTON and LOUISVILLE, Ky., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform...

1 year ago - GlobeNewsWire